The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease
Open accessThe DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Better treatment during early stages of chronic kidney disease (CKD) may slow progression to end-stage renal disease and decrease associated complications and medical costs. Achieving early treatment of CKD is challenging, however, because a large fraction of persons with CKD are unaware of having this disease. Screening for CKD is one important method for increasing awareness. We examined the cost-effectiveness of identifying persons for early-stage CKD screening (i.e., screening for moderate albuminuria) using published CKD risk scores. METHODS: We used the CKD Health Policy Model, a micro-simulation model, to simulate the cost-effectiveness of using CKD two published risk scores by Bang et al. and Kshirsagar et al. to identify persons in the US for CKD screening with testing for albuminuria. Alternative risk score thresholds were tested (0.20, 0.15, 0.10, 0.05, and 0.02) above which persons were assigned to receive screening at alternative intervals (1-, 2-, and 5-year) for follow-up screening if the first screening was negative. We examined incremental cost-effectiveness ratios (ICERs), incremental lifetime costs divided by incremental lifetime QALYs, relative to the next higher screening threshold to assess cost-effectiveness. Cost-effective scenarios were determined as those with ICERs less than $50,000 per QALY. Among the cost-effective scenarios, the optimal scenario was determined as the one that resulted in the highest lifetime QALYs. RESULTS: ICERs ranged from $8,823 per QALY to $124,626 per QALY for the Bang et al. risk score and $6,342 per QALY to $405,861 per QALY for the Kshirsagar et al. risk score. The Bang et al. risk score with a threshold of 0.02 and 2-year follow-up screening was found to be optimal because it had an ICER less than $50,000 per QALY and resulted in the highest lifetime QALYs. CONCLUSIONS: This study indicates that using these CKD risk scores may allow clinicians to cost-effectively identify a broader population for CKD screening with testing for albuminuria and potentially detect people with CKD at earlier stages of the disease than current approaches of screening only persons with diabetes or hypertension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Measurement of a spot urine sample for albumin alone (whether by immunoassay or by using a sensitive dipstick test specific for albuminuria) without simultaneously measuring urine creatinine is less expensive but susceptible to false-negative and falsepositive determinations as a result of variation in urine concentration due to hydration (7).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Measurement of a spot urine sample for albumin alone (whether by immunoassay or by using a sensitive dipstick test specific for albuminuria) without simultaneously measuring urine creatinine is less expensive but susceptible to falsenegative and false-positive determinations as a result of variation in urine concentration due to hydration (8).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [8]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Nakao, N., Yoshimura, A., Morita, H., Takada, M., Kayano, T., & Ideura, T. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12229-5 · Cited by 970
RetractedAhmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Prevalence of Chronic Kidney Disease in the United States
Coresh, J., Selvin, E., Stevens, L. A., Manzi, J., Kusek, J. W., Eggers, P., Van Lente, F., & Levey, A. S. (2007) · JAMA · doi:10.1001/jama.298.17.2038 · Cited by 4,895
Recommendations of the Panel on Cost-Effectiveness in Health and Medicine
Weinstein, M. C. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540150055031 · Cited by 2,455
Weiner, D. E., Tighiouart, H., Amin, M. G., Stark, P. C., MacLeod, B., Griffith, J. L., Salem, D. N., Levey, A. S., & Sarnak, M. J. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000123691.46138.e2 · Cited by 1,176
US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States
Saran, R., Li, Y., Robinson, B., Abbott, K. C., Agodoa, L. Y. C., Ayanian, J., Bragg-Gresham, J., Balkrishnan, R., Chen, J. L. T., Cope, E., et al. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.12.014 · Cited by 1,155
Jafar, T. H., Schmid, C. H., Landa, M., Giatras, I., Toto, R., Remuzzi, G., Maschio, G., Brenner, B. M., Kamper, A., Zucchelli, P., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-2-200107170-00007 · Cited by 1,092
Research works printed but not linked: 1
- Weinstein M, Siegel J, Gold M, Kamlet M, Russell L. Cost-effectiveness in heath and medicine. New York: Oxford University Press; 1996.
Cited by
Shlipak, M. G., Tummalapalli, S. L., Boulware, L. E., Grams, M. E., Ix, J. H., Jha, V., Kengne, A.-P., Madero, M., Mihaylova, B., Tangri, N., et al. (2021) · Kidney International · doi:10.1016/j.kint.2020.10.012 · Cited by 581
“testing, expected prevalence and incidence (testing yield) of CKD, and costs of confirmatory tests and treatment, among others.(30,108,109)”
BackgroundSelf-citation11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s011 · Cited by 395
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s011 · Cited by 275
11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s011 · Cited by 344
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s011 · Cited by 289
Metadata
- Authors
- Initiative, O. B. O. T. C. F. D. C. A. P. C., Yarnoff, B. O., Hoerger, T. J., Simpson, S. K., Leib, A., Burrows, N. R., Shrestha, S. S., & Pavkov, M. E.
- Affiliations
- RTI International (US)
- Centers for Disease Control and Prevention (US)
- Corresponding author
- Yarnoff, Benjamin O.
- Venue
- BMC Nephrology
- Published
- 2017-03-13
- Volume
- 18
- Issue
- 1
- Pages
- 85-85
- ISSN
- 1471-2369 (ISSN-L)
- PMC
- PMC5347833
- OpenAlex
- W2595986895
- Semantic Scholar
- a612b66a5842bf1578243d17758e26f87ed30f81
- Cited by
- 55
- References
- 36
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 9 · 2023: 7 · 2022: 7 · 2021: 4 · 2020: 9 · 2019: 3 · 2018: 2
- FWCI
- 6.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- BMC Nephrology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Centers for Disease Control and Prevention (200-2008-27958)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Keywords
- chronic kidney disease, CKD screening, albuminuria, cost-effectiveness, screening thresholds, quality-adjusted life years, early detection
- MeSH terms
- Adult, Aged, Albuminuria, Cost-Benefit Analysis, Female, Humans, Male, Mass Screening, Middle Aged, North Carolina, Sensitivity and Specificity, Reproducibility of Results, Comorbidity, Prevalence, Health Care Costs, Cost of Illness, Risk Assessment, Early Diagnosis, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease. https://app.cochat.ai/papers/10.1186/s12882-017-0497-6
- The paper
- Initiative, O. B. O. T. C. F. D. C. A. P. C., Yarnoff, B. O., Hoerger, T. J., Simpson, S. K., Leib, A., Burrows, N. R., Shrestha, S. S., & Pavkov, M. E. (2017). The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease. BMC Nephrology. https://doi.org/10.1186/s12882-017-0497-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.